Edwards Lifesciences (NYSE:EW) VP Sells 619 Shares of Stock

Edwards Lifesciences Corporation (NYSE:EW) VP Daniel Lippis sold 619 shares of the business’s stock in a transaction that occurred on Thursday, October 8th. The stock was sold at an average price of $85.65, for a total value of $53,017.35. Following the sale, the vice president directly owned 40,034 shares in the company, valued at $3,428,912.10. The trade was a 1.52% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Edwards Lifesciences Trading Down 1.9%

Shares of NYSE:EW traded down $1.60 during trading on Thursday, hitting $84.18. The company had a trading volume of 6,522,001 shares, compared to its average volume of 4,524,115. The stock has a market cap of $48.47 billion, a price-to-earnings ratio of 48.38, a price-to-earnings-growth ratio of 2.27 and a beta of 0.87. The company has a debt-to-equity ratio of 0.06, a current ratio of 4.52 and a quick ratio of 3.77. The company has a fifty day simple moving average of $88.79 and a two-hundred day simple moving average of $86.15. Edwards Lifesciences Corporation has a one year low of $72.30 and a one year high of $96.29.

Edwards Lifesciences (NYSE:EW) last released its earnings results on Thursday, July 23rd. The medical research company reported $0.78 earnings per share for the quarter, beating the consensus estimate of $0.74 by $0.04. The firm had revenue of $1.74 billion for the quarter, compared to the consensus estimate of $1.70 billion. Edwards Lifesciences had a return on equity of 15.68% and a net margin of 15.43%.The company’s revenue for the quarter was up 13.6% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.67 EPS. Edwards Lifesciences has set its Q3 2026 guidance at 0.710-0.770 EPS and its FY 2026 guidance at 2.950-3.050 EPS. As a group, equities analysts forecast that Edwards Lifesciences Corporation will post 3 earnings per share for the current year.

Analysts Set New Price Targets

Several equities research analysts have recently issued reports on EW shares. Citigroup restated a “buy” rating on shares of Edwards Lifesciences in a report on Monday. Royal Bank Of Canada upped their price target on shares of Edwards Lifesciences from $100.00 to $110.00 and gave the company an “outperform” rating in a report on Monday, July 13th. UBS Group reissued a “buy” rating on shares of Edwards Lifesciences in a research report on Thursday. Evercore restated an “outperform” rating and set a $100.00 target price on shares of Edwards Lifesciences in a research report on Monday, July 6th. Finally, Wall Street Zen cut Edwards Lifesciences from a “buy” rating to a “hold” rating in a research note on Saturday, September 26th. One equities research analyst has rated the stock with a Strong Buy rating, sixteen have given a Buy rating and five have issued a Hold rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $100.27.

Institutional Investors Weigh In On Edwards Lifesciences

A number of institutional investors and hedge funds have recently added to or reduced their stakes in EW. Pin Oak Investment Advisors Inc. bought a new position in Edwards Lifesciences in the 2nd quarter worth about $26,000. TrinityBridge Ltd purchased a new position in shares of Edwards Lifesciences during the second quarter worth approximately $27,000. MV Capital Management Inc. bought a new stake in shares of Edwards Lifesciences during the fourth quarter valued at approximately $26,000. Hanson & Doremus Investment Management bought a new stake in shares of Edwards Lifesciences during the first quarter valued at approximately $25,000. Finally, Hilton Head Capital Partners LLC purchased a new stake in shares of Edwards Lifesciences in the fourth quarter valued at approximately $28,000. Institutional investors own 79.46% of the company’s stock.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation is a medical technology company focused on therapies for structural heart disease and other cardiovascular conditions. The company develops and manufactures heart valve replacement and repair technologies, including transcatheter aortic valve replacement systems, surgical heart valves, transcatheter mitral and tricuspid therapies, and related delivery systems and accessories.

Founded in 1958 by engineer Miles “Lowell” Edwards, the company helped pioneer artificial heart valves and has played a significant role in the development of transcatheter valve replacement.